한글목차

세계 ePRO, 전자환자 일지 및 eCOA 시장 규모는 2030년까지 47억 달러에 이를 것으로 도달할 전망입니다.

세계 ePRO, 전자환자일지 및 eCOA 시장 규모는 2023년 18억 달러에 이르고, 분석 기간 동안 복합 연간 성장률(CAGR) 15.0%로 성장하며 2030년 47억 달러에 달할 것으로 예측됩니다. ePROs 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 16.7%로 추정됩니다.

미국 시장은 6억 2,980만 달러, 중국은 복합 연간 성장률(CAGR) 17.9%로 성장 할 것으로 예측됩니다.

미국의 ePRO, 전자환자일지 및 eCOA 시장 규모는 2023년 6억 2,980만 달러에 이르고, 세계 2위 경제대국인 중국은 2030년까지 6억 460만 달러에 이를 것으로 예측 예측 기간 동안 분석 기간 중에는 복합 연간 성장률(CAGR) 17.9%로 성장할 전망입니다. 다른 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 각각 분석 기간 중에 12.4%와 14.3%의 복합 연간 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 약 13.6%로 성장할 것으로 예측됩니다.

세계 ePRO, 전자 환자 일지 및 eCOA 시장 : 주요 동향 및 촉진요인 요약

ePRO, 전자 환자 일지 및 eCOA는 임상시험 및 의료 현장에서 환자로부터 직접 데이터를 수집하는 데 사용되는 디지털 플랫폼입니다. ePRO 시스템은 보통 모바일 장치 및 기타 웹 기반 애플리케이션을 통해 건강 상태, 치료 어드밴스, 증상에 대한 환자 데이터를 전자적으로 수집하는 데 사용됩니다. 전자 환자 일지는 환자가 건강 상태에 대한 일상적인 관찰을 기록하는 디지털 수단을 제공하며, 만성 질환 관리에 특히 유용합니다. eCOA는 이러한 도구를 포함하며 디지털 인터페이스를 통해 수집된 임상 의사 보고서 결과(ClinROs), 관찰자 보고서 결과(ObsROs) 및 성능 결과(PerfOs)를 포함합니다. 이러한 도구는 데이터 수집의 정확성을 높이고 환자 참여를 강화하며 복잡한 건강 데이터를 실시간으로 수집하는 프로세스를 간소화하기 위해 종이 기반 방법을 대체하도록 설계되었습니다. 되었습니다.

ePRO, 전자환자일지 및 eCOA 시스템의 도입은 의료의 디지털 전환과 제약산업이 환자 중심의 연구를 중시함으로써 추진되고 있습니다. 이러한 디지털 툴을 활용함으로써 임상 연구자들은 보다 신뢰할 수 있는 데이터를 적시에 얻어 임상시험의 질과 효율성을 높일 수 있습니다. 또한 이러한 기술은 프로토콜 준수를 보장하고 실시간 모니터링 및 감사 기능을 촉진하여 규제 준수를 지원합니다. 환자의 경우 디지털 도구는 집에서 시험에 참여할 수 있는 편의성을 제공하고 적시에 알림 및 건강 관리 제공업체와의 간편한 커뮤니케이션 채널을 통해 시험 프로토콜 준수를 향상시킵니다. 또한, 이러한 기술은 장기간의 지속적인 환자 참여와 정확한 데이터 수집이 중요한 장기 시험에 필수적입니다.

ePRO, 전자 환자 일지 및 eCOA 시장의 성장은 모바일 건강 용도의 기술적 진보와 원격 의료 실습의 수용 확대 등 여러 요인에 의해 야기됩니다. 스마트폰 및 태블릿이 보급됨에 따라 더 많은 환자와 임상의가 정교한 건강 모니터링 도구에 쉽게 액세스할 수 있습니다. 규제기관과 보건당국은 임상 결과 개선에서 실시간 환자 데이터의 가치를 점점 더 인식하고 있으며, 이는 세계 의료 및 연구 환경에서 이러한 시스템의 채택을 뒷받침하고 있습니다. 또한, 환자 중심의 치료 접근법에 대한 수요가 증가하고 임상시험에서 효율적인 데이터 관리의 필요성이 이 시장의 주요 촉진요인이 되고 있습니다. 의료 기술에 대한 소비자의 행동은 극적으로 변화하고 있으며, 환자는 현재 자신의 건강 관리에 적극적인 역할을 기대하고 있으며, 이는 ePRO, 전자 환자 일지 및 eCOA의 기능과 잘 일치합니다. 이러한 동향은 유행 후 디지털 건강 솔루션의 지속적인 추진과 함께 시장의 역동적인 확장과 진화를 뒷받침합니다.

조사 대상 기업 예(전 85건)

• Anju Software, Inc.
• ArisGlobal LLC
• Castor EDC
• Clario
• Climedo Health GmbH
• ClinCapture
• Dassault Systemes SE
• eClinical Solutions LLC
• ICON plc
• IQVIA Holdings, Inc.
• Kayentis, SAS
• MedNet Solutions, Inc.
• Signant Health
• TransPerfect

목차

제1장 조사 방법

제2장 주요 요약

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 시장 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global ePRO, E-Patient Diaries and eCOA Market to Reach US$4.7 Billion by 2030

The global market for ePRO, E-Patient Diaries and eCOA estimated at US$1.8 Billion in the year 2023, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 15.0% over the analysis period 2023-2030. eClinical Outcome Assessments (eCOAs), one of the segments analyzed in the report, is expected to record a 15.2% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the ePatient Reported Outcomes (ePROs) segment is estimated at 16.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$629.8 Million While China is Forecast to Grow at 17.9% CAGR

The ePRO, E-Patient Diaries and eCOA market in the U.S. is estimated at US$629.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$604.6 Million by the year 2030 trailing a CAGR of 17.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.4% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.6% CAGR.

Global ePRO, E-Patient Diaries and Ecoa Market- Key Trends and Drivers Summarized

Electronic Patient-Reported Outcomes (ePROs), e-Patient Diaries, and electronic Clinical Outcome Assessments (eCOAs) are digital platforms used in clinical trials and healthcare settings to collect data directly from patients. ePRO systems are used to electronically capture patient data on health status, treatment adherence, and symptoms, usually via mobile devices or other web-based applications. E-Patient Diaries provide patients with a digital means to record daily observations about their health condition, which can be particularly valuable for chronic diseases management. eCOAs encompass these tools and extend to include clinician-reported outcomes (ClinROs), observer-reported outcomes (ObsROs), and performance outcomes (PerfOs) gathered through digital interfaces. These tools are designed to replace paper-based methods, aiming to improve the accuracy of data collection, enhance patient engagement, and streamline the process of capturing complex health data in real time.

The adoption of ePRO, e-Patient Diaries, and eCOA systems is being propelled by the digital transformation in healthcare and the pharmaceutical industry’s focus on patient-centered research. By utilizing these digital tools, clinical researchers can obtain more reliable and timely data, enhancing the quality and efficiency of clinical trials. These technologies also support regulatory compliance by ensuring adherence to protocols and facilitating real-time monitoring and auditing capabilities. For patients, digital tools offer the convenience of participating in studies from home and improve compliance with study protocols through timely reminders and easier communication channels with healthcare providers. Moreover, these technologies are integral in long-term studies where consistent patient engagement and accurate data collection over extended periods are crucial.

The growth in the ePRO, e-Patient Diaries, and eCOA market is driven by several factors, including technological advancements in mobile health applications and increased acceptance of telehealth practices. As smartphones and tablets become more prevalent, more patients and clinicians are able to access sophisticated health monitoring tools with ease. Regulatory bodies and health authorities are increasingly recognizing the value of real-time patient data in improving clinical outcomes, which is encouraging the adoption of these systems across global healthcare and research settings. Additionally, the growing demand for patient-centric treatment approaches and the need for efficient data management in clinical trials are key drivers of this market. Consumer behavior towards health technology has shifted dramatically, with patients now expecting more active roles in managing their health, which aligns well with the capabilities of ePROs, e-Patient Diaries, and eCOAs. These trends, combined with the ongoing push for digital health solutions post-pandemic, underscore a dynamic expansion and evolution in the market.

Select Competitors (Total 85 Featured) -

• Anju Software, Inc.
• ArisGlobal LLC
• Castor EDC
• Clario
• Climedo Health GmbH
• ClinCapture
• Dassault Systemes SE
• eClinical Solutions LLC
• ICON plc
• IQVIA Holdings, Inc.
• Kayentis, SAS
• MedNet Solutions, Inc.
• Signant Health
• TransPerfect

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Pivotal Role of eCOA, ePRO and Patient Engagement in Transforming Patient Centricity
  • An Introduction to ePRO, E-Patient Diaries and eCOA
  • Influencer Market Insights
  • Global Economic Update
  • Global Market Outlook
  • eCOA: The Largest Category
  • ePRO Offers Tremendous Opportunities in Improving Healthcare System
  • Competition
  • ePRO, E-Patient Diaries and eCOA - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Recent Market Activity
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Digitalization of Healthcare Services and Rising Importance of Electronic Data Capture Technologies to Fuel Market Growth
  • Global Digital Health Market: Annual Revenues in US$ Million by Region/Country for 2020 and 2027
  • Patient Engagement Practices of the Future to be Shaped by Trends of Increased Use of Personal Devices and Passive Data
  • Key Patient Engagement Technology Trends and Innovations
  • eCOA & ePRO: A Powerful Duo Serving Clinical Trials with Electronic Data Collection
  • Rise in Clinical Trials Drives Need for ePRO, ePatient Diaries, and eCOA Solutions
  • Number of Registered Clinical Studies (in Thousands) Worldwide for the Period 2010-2023
  • Clinical Trials in the US: % Change in Trial Starts by Therapy Area for 2020 Vs 2019
  • Percentage Breakdown of Endpoint Adjudication Committees (EAC) Trials by Therapeutic Area: 2023E
  • COVID-19 Pandemic Triggers Technology Adoption in Clinical Trials
  • Digital Health Venture Funding in the US (in $ Billion) for the Years 2015-2023
  • Trends in Clinical Trials Space to Influence Market Demand
  • Shift towards Decentralized/Virtual Clinical Trials to Boost Market Prospects
  • Global Virtual Clinical Trials Market Size (in US$ Billion) for the Years 2022, 2024, 2026 and 2028
  • Global Virtual Clinical Trials Market by Indication (in %) for 2023E
  • Decentralized Clinical Trials Driving Greater Demand for Patient-Centric Drug Development
  • Role of eCOA & ePRO in Enhancing Data Accuracy of Decentralized Clinical Trials
  • Growing Volumes of Data Generation in Decentralized Trials: A Challenge
  • Adoption of Digital Technologies in Contract Research Organizations Bodes Well for the Market
  • Global Contract Research Outsourcing Market Revenues (US$ Million) by Geographic Region/Country for 2020 and 2027
  • Pharmaceutical R&D Spending Worldwide (USD Billion): 2015-2025
  • COVID-19 and Implications for Drug Development Regulations & Processes
  • Rise in Telemedicine Services Present Market Opportunities
  • Global Telehealth Market (In US$ Million) for Years 2022, 2024, 2026 and 2028
  • Growing Adoption of Mobile Technologies and BYOD Trend in Healthcare Industry Boosts Market Prospects
  • Smartphone Adoption Rate as a Percentage of Connections by Region for 2022 and 2030
  • Mobile Device Use in Healthcare Settings: % Usage by Type of Mobile Device
  • Electronic Patient Record (ePRO) Solutions Emerge as Ideal Replacements for Paper-Based PRO systems
  • Moving over Paper Pains & Mastering the Art of Real-Time Data Collection with ePRO
  • Delivering Better Data: A Key Benefit of ePRO
  • Factors Ensuring Success of ePRO Implementations
  • ePatient Reported Outcomes (PROs) Gain Importance in Oncology Studies
  • Advances in ePRO Technologies Promise Better Clinical Decision Making in Healthcare Systems
  • Integrating AI into ePRO Improves the Efficiency of ePRO Data Collection and Assessment
  • Data Integrity, Security & Privacy: Key Priorities for ePRO Solutions
  • Electronic Clinical Outcome Assessment Solution (eCOA) Market: Poised for Growth
  • Global eCOA Market Breakdown by Delivery Mode (in %) for 2023E
  • eCOA Usage by Clinical Trial Phase (in %) for 2021
  • eCOA Grants The Best Route to Improve Data Quality & Patient Experience for Clinical Trials
  • Benefits Offered by eCOA Systems over the Paper-Based Systems in Trials
  • How to Successfully Implement eCOA Systems in Clinical Trials?
  • New Technologies & Approaches with Potential to Augment Statistical Prowess of eCOA
  • Technological Trends Transforming eCOA Solutions Market
  • Future Trends in eCOA Market: A Review
  • UAT, Challenges and Embedded UAT for eCOAs
  • Benefits of BYOD for eCOAs
  • E-Patient Diaries: Significant Advantages over Paper Diaries to Drive Market
  • Major Benefits of ePatient Diary
  • eCOA & ePRO to Help Mental Health Research Shed the Taboo Status & Move Forward
  • Intriguing Perks of eCOA & ePRO for Mental Health Research
  • Increase in Healthcare Spending to Propel Demand
  • World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • Increasing Burden of Chronic Diseases and Focus on Drug Development, Therapies and Vaccines Boost Market
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Global Annual Medical Cost of CVD in US$ Billion (2010-2030)
  • World Diabetes and Population Statistics (2019, 2030 & 2045)
  • Aging World Population to Drive Market Growth
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Challenges Facing Companies Implementing eCOA, ePRO & Patient-Centric Clinical Trials
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World ePRO, E-Patient Diaries and eCOA Market Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for eClinical Outcome Assessments (eCOAs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for eClinical Outcome Assessments (eCOAs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for ePatient Reported Outcomes (ePROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for ePatient Reported Outcomes (ePROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Clinician Reported Outcomes (ClinROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Clinician Reported Outcomes (ClinROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for ePatient Diaries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 11: World 7-Year Perspective for ePatient Diaries by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Performance Outcomes (PerfOs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 13: World 7-Year Perspective for Performance Outcomes (PerfOs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Observer Reported Outcomes (ObsROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World 7-Year Perspective for Observer Reported Outcomes (ObsROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: World 7-Year Perspective for Clinical Trial Sponsors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Contract Research Organizations (CROs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 19: World 7-Year Perspective for Contract Research Organizations (CROs) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Academic Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 23: World 7-Year Perspective for Academic Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 25: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: USA 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Canada 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• JAPAN
  • TABLE 34: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 35: Japan 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 36: Japan Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 37: Japan 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• CHINA
  • TABLE 38: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: China 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 40: China Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 41: China 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• EUROPE
  • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 42: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 43: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 44: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 46: Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• FRANCE
  • TABLE 48: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 49: France 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 50: France Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: France 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• GERMANY
  • TABLE 52: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 53: Germany 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 54: Germany Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 55: Germany 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• ITALY
  • TABLE 56: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Italy 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 58: Italy Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 59: Italy 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• UNITED KINGDOM
  • TABLE 60: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 61: UK 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 62: UK Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: UK 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 64: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 65: Rest of Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 66: Rest of Europe Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Rest of Europe 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• ASIA-PACIFIC
  • ePRO, E-Patient Diaries and eCOA Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Asia-Pacific 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 70: Asia-Pacific Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 71: Asia-Pacific 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 72: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by Solution Type - eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 73: Rest of World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by Solution Type - Percentage Breakdown of Value Revenues for eClinical Outcome Assessments (eCOAs), ePatient Reported Outcomes (ePROs), Clinician Reported Outcomes (ClinROs), ePatient Diaries, Performance Outcomes (PerfOs) and Observer Reported Outcomes (ObsROs) for the Years 2024 & 2030
  • TABLE 74: Rest of World Recent Past, Current & Future Analysis for ePRO, E-Patient Diaries and eCOA by End-Use - Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Rest of World 7-Year Perspective for ePRO, E-Patient Diaries and eCOA by End-Use - Percentage Breakdown of Value Revenues for Clinical Trial Sponsors, Contract Research Organizations (CROs), Hospitals, Academic Institutes and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION